Allogene Therapeutics Inc (NAS:ALLO)
$ 2.02 -0.12 (-5.61%) Market Cap: 448.70 Mil Enterprise Value: 252.75 Mil PE Ratio: 0 PB Ratio: 0.91 GF Score: 36/100

Allogene Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 04:15PM GMT
Release Date Price: $3.17 (+3.93%)
Brian Cheng JPMorgan;CIBC;Analyst

Good morning. Thanks for joining us for another session at the 42nd JPMorgan Healthcare Conference. I'm Brian Cheng, one of the Senior Biotech Analysts here at the firm. I'm joined by my associate Gensym losing the audience on stage, we have Allogene CEO, David Chang. I'll pass the mic to David briefly to for a short presentation, followed by a live Q&A either joining us live and you can some of the questions for the team through our conference portal. David, the stage is yours.

David Chang
Allogene Therapeutics Inc - President, Chief Executive Officer, Co-Founder, Director

Brian, Happy New Year. And thanks for having me on podium today and for those who in the audience thanks for interest in what we are doing at Allogene. In a legal disclaimer and this is the beginning of the year. And this year, we have made some very important announcements about how we are redirecting our development program.

The four components of the announcements: one, advancing our lead program Cema-cel Cema cap

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot